Leukemia Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with Leukemia, or supporting a loved one through their cancer journey? The Cancer Connect Leukemia Information Center has current, evidence-based information for you. Get the facts about leukemia early detection, treatment, and survivorship, and stay up to date with ongoing leukemia research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Leukemia Community is the leading Social Media Application for Leukemia patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Chronic lymphoid leukemia (CLL) patients treated with Imbruvica™ showed improved survival when compared to those treated with Arzerra®. Arzerra Plus Chlorambucil Approved for Previously Untreated CLL
The FDA has approved the use of Arzerra in combination with chlorambucil in previously untreated patients with CLL. SYNRIBO® Approved for use in Chronic Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) has granted full approval of SYNRIBO®...
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse... Caregivers
What is Caregiving and Who are Caregivers? Caregivers are individuals who provide...
Sean Swarner is a master of setting a goal and achieving it. So when he... Connecting for a Cure
The Leukemia & Lymphoma Society Is United for Support, Research, and, Ultimately, a Cure The Bone Marrow Foundation
For many patients and families facing bone marrow, stem cell, and cord blood transplant,...
Leukemia Clinical Trials
EXPLORE – Examination of PNH, by Level of CD59 on Red and white blood cells, in bone marrow failure syndromes (EXPLORE).